Ligand Pharmaceuticals (LGND) saw its stock price plummet 5.25% in pre-market trading on Thursday following the release of its first-quarter 2025 financial results. The biopharmaceutical company reported significant losses, disappointing investors and triggering a sell-off.
According to the earnings report, Ligand posted a basic earnings per share (EPS) of -$2.21 for Q1 2025. The company's operating income came in at -$36.216 million, while its pretax profit stood at a concerning -$50.18 million. These figures paint a picture of substantial financial challenges faced by the company in the first quarter.
Despite the negative results, Ligand Pharmaceuticals has reaffirmed its financial guidance for 2025, suggesting that the company remains optimistic about its long-term prospects. However, the market's immediate reaction indicates that investors are more focused on the current performance rather than future projections. As trading continues, it remains to be seen whether Ligand can regain investor confidence and reverse this downward trend.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.